{"pmid":32473230,"title":"Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.","text":["Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.","No specific treatment against SARS-CoV-2 is available after 6 months of COVID-19 worldwide outbreak Antivirals could decrease the viral load and reduce direct and indirect damages of SARSCoV-2 infection Ritonavir-bosted lopinavir is effective against SARS-CoV-2 in vitro Sequential virological and pharmacological monitoring helped to understand the efficacy of ritonavir-boosted lopinavir in a SARS-CoV-2 infected patient Ritonavir-boosted lopinavir could be proposed as early treatment for SARS-CoV-2 infection.","J Infect","Klement-Frutos, Elise","Burrel, Sonia","Peytavin, Gilles","Marot, Stephane","Le, Minh P","Godefroy, Nagisa","Calvez, Vincent","Marcelin, Anne-Genevieve","Caumes, Eric","Pourcher, Valerie","Boutolleau, David","32473230"],"abstract":["No specific treatment against SARS-CoV-2 is available after 6 months of COVID-19 worldwide outbreak Antivirals could decrease the viral load and reduce direct and indirect damages of SARSCoV-2 infection Ritonavir-bosted lopinavir is effective against SARS-CoV-2 in vitro Sequential virological and pharmacological monitoring helped to understand the efficacy of ritonavir-boosted lopinavir in a SARS-CoV-2 infected patient Ritonavir-boosted lopinavir could be proposed as early treatment for SARS-CoV-2 infection."],"journal":"J Infect","authors":["Klement-Frutos, Elise","Burrel, Sonia","Peytavin, Gilles","Marot, Stephane","Le, Minh P","Godefroy, Nagisa","Calvez, Vincent","Marcelin, Anne-Genevieve","Caumes, Eric","Pourcher, Valerie","Boutolleau, David"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473230","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jinf.2020.05.039","keywords":["covid-19","sars-cov-2","lopinavir","pharmacology","protease inhibitor","virology"],"locations":["Ritonavir"],"topics":["Treatment"],"weight":1,"_version_":1668255193255378944,"score":9.490897,"similar":[{"pmid":32460458,"title":"In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.","text":["In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.","Background/Aims: As the coronavirus disease-2019 global pandemic progresses, screening of antiviral agents effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is urgently needed. In addition, considering the viral load kinetics of SARS-CoV-2, which peaks early in the illness, and the massive burden of the disease, which may increase in the near future, identifying well-tolerated oral antivirals becomes increasingly important. We examined the in vitro activity of lopinavir/ritonavir and hydroxychloroquine on SARS-CoV-2, at concentrations which can be used to treat coronavirus-19 patients with little concern of toxicity. Methods: Lopinavir/ritonavir (7/1.75 mug/mL), hydroxychloroquine base (1 or 2 mug/mL), or a combination thereof were administered 1 hour after the inoculation of SARS-CoV-2 to Vero cells at a multiplicity of infection of 0.05. We examined cytopathic effects of virus 48 hours after administration of the respective treatments and measured viral loads at three time points (0, 24, and 48 hours post-treatment) by quantitative real-time reverse-transcription polymerase chain reaction, and compared the results obtained from the different antiviral regimens tested. Results: The severity of cytopathic effects was lower in lopinavir/ritonavir-treated cells, and viral load was significantly reduced in this group compared with the control group (p < 0.001). However, hydroxychloroquine did not show significant inhibitory effects on anti-SARS-CoV-2-mediated cytotoxicity or on viral load at either concentration. Conclusions: Lopinavir/ritonavir showed significant inhibitory effects on SARS-CoV-2 in vitro at its usual plasma concentration. However, the in vitro antiviral activity of hydroxychloroquine at concentrations commonly used in humans was minimal, whether used alone or in combination with lopinavir/ritonavir.","Korean J Intern Med","Kang, Chang Kyung","Seong, Moon-Woo","Choi, Su-Jin","Kim, Taek Soo","Choe, Pyoeng Gyun","Song, Sang Hoon","Kim, Nam-Joong","Park, Wan Beom","Oh, Myoung-Don","32460458"],"abstract":["Background/Aims: As the coronavirus disease-2019 global pandemic progresses, screening of antiviral agents effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is urgently needed. In addition, considering the viral load kinetics of SARS-CoV-2, which peaks early in the illness, and the massive burden of the disease, which may increase in the near future, identifying well-tolerated oral antivirals becomes increasingly important. We examined the in vitro activity of lopinavir/ritonavir and hydroxychloroquine on SARS-CoV-2, at concentrations which can be used to treat coronavirus-19 patients with little concern of toxicity. Methods: Lopinavir/ritonavir (7/1.75 mug/mL), hydroxychloroquine base (1 or 2 mug/mL), or a combination thereof were administered 1 hour after the inoculation of SARS-CoV-2 to Vero cells at a multiplicity of infection of 0.05. We examined cytopathic effects of virus 48 hours after administration of the respective treatments and measured viral loads at three time points (0, 24, and 48 hours post-treatment) by quantitative real-time reverse-transcription polymerase chain reaction, and compared the results obtained from the different antiviral regimens tested. Results: The severity of cytopathic effects was lower in lopinavir/ritonavir-treated cells, and viral load was significantly reduced in this group compared with the control group (p < 0.001). However, hydroxychloroquine did not show significant inhibitory effects on anti-SARS-CoV-2-mediated cytotoxicity or on viral load at either concentration. Conclusions: Lopinavir/ritonavir showed significant inhibitory effects on SARS-CoV-2 in vitro at its usual plasma concentration. However, the in vitro antiviral activity of hydroxychloroquine at concentrations commonly used in humans was minimal, whether used alone or in combination with lopinavir/ritonavir."],"journal":"Korean J Intern Med","authors":["Kang, Chang Kyung","Seong, Moon-Woo","Choi, Su-Jin","Kim, Taek Soo","Choe, Pyoeng Gyun","Song, Sang Hoon","Kim, Nam-Joong","Park, Wan Beom","Oh, Myoung-Don"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32460458","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3904/kjim.2020.157","keywords":["covid-19","hydroxychloroquine","in vitro techniques","lopinavir/ritonavir","severe acute respiratory syndrome coronavirus 2"],"e_drugs":["Hydroxychloroquine","lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1668079521432076288,"score":285.7705},{"pmid":32283143,"pmcid":"PMC7195393","title":"Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.","text":["Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.","Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases) and arbidol group (16 cases). Lopinavir/ritonavir group received 400 mg/100mg of Lopinavir/ritonavir, twice a day for a week, while the arbidol group was given 0.2 g arbidol, three times a day. Data from these patients were retrospectively analyzed. The cycle threshold values of open reading frame 1ab and nucleocapsid genes by RT-PCR assay were monitored during antiviral therapy. None of the patients developed severe pneumonia or ARDS. There was no difference in fever duration between the two groups (P=0.61). On day 14 after the admission, no viral load was detected in arbidol group, but the viral load was found in 15(44.1%) patients treated with lopinavir/ritonavir. Patients in the arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group (P<0.01). Moreover, no apparent side effects were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19.","J Infect","Zhu, Zhen","Lu, Zhaohui","Xu, Tianmin","Chen, Cong","Yang, Gang","Zha, Tao","Lu, Jianchun","Xue, Yuan","32283143"],"abstract":["Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases) and arbidol group (16 cases). Lopinavir/ritonavir group received 400 mg/100mg of Lopinavir/ritonavir, twice a day for a week, while the arbidol group was given 0.2 g arbidol, three times a day. Data from these patients were retrospectively analyzed. The cycle threshold values of open reading frame 1ab and nucleocapsid genes by RT-PCR assay were monitored during antiviral therapy. None of the patients developed severe pneumonia or ARDS. There was no difference in fever duration between the two groups (P=0.61). On day 14 after the admission, no viral load was detected in arbidol group, but the viral load was found in 15(44.1%) patients treated with lopinavir/ritonavir. Patients in the arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group (P<0.01). Moreover, no apparent side effects were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19."],"journal":"J Infect","authors":["Zhu, Zhen","Lu, Zhaohui","Xu, Tianmin","Chen, Cong","Yang, Gang","Zha, Tao","Lu, Jianchun","Xue, Yuan"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283143","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.03.060","keywords":["antiviral therapy","covid-19","ct value","pneumonia","sars-cov2"],"e_drugs":["arbidol","lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1666138491439808512,"score":270.71234},{"pmid":32187464,"pmcid":"PMC7121492","title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.","text":["A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.","BACKGROUND: No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. METHODS: We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first. RESULTS: A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group. Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events. CONCLUSIONS: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).","N Engl J Med","Cao, Bin","Wang, Yeming","Wen, Danning","Liu, Wen","Wang, Jingli","Fan, Guohui","Ruan, Lianguo","Song, Bin","Cai, Yanping","Wei, Ming","Li, Xingwang","Xia, Jiaan","Chen, Nanshan","Xiang, Jie","Yu, Ting","Bai, Tao","Xie, Xuelei","Zhang, Li","Li, Caihong","Yuan, Ye","Chen, Hua","Li, Huadong","Huang, Hanping","Tu, Shengjing","Gong, Fengyun","Liu, Ying","Wei, Yuan","Dong, Chongya","Zhou, Fei","Gu, Xiaoying","Xu, Jiuyang","Liu, Zhibo","Zhang, Yi","Li, Hui","Shang, Lianhan","Wang, Ke","Li, Kunxia","Zhou, Xia","Dong, Xuan","Qu, Zhaohui","Lu, Sixia","Hu, Xujuan","Ruan, Shunan","Luo, Shanshan","Wu, Jing","Peng, Lu","Cheng, Fang","Pan, Lihong","Zou, Jun","Jia, Chunmin","Wang, Juan","Liu, Xia","Wang, Shuzhen","Wu, Xudong","Ge, Qin","He, Jing","Zhan, Haiyan","Qiu, Fang","Guo, Li","Huang, Chaolin","Jaki, Thomas","Hayden, Frederick G","Horby, Peter W","Zhang, Dingyu","Wang, Chen","32187464"],"abstract":["BACKGROUND: No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. METHODS: We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first. RESULTS: A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group. Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events. CONCLUSIONS: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.)."],"journal":"N Engl J Med","authors":["Cao, Bin","Wang, Yeming","Wen, Danning","Liu, Wen","Wang, Jingli","Fan, Guohui","Ruan, Lianguo","Song, Bin","Cai, Yanping","Wei, Ming","Li, Xingwang","Xia, Jiaan","Chen, Nanshan","Xiang, Jie","Yu, Ting","Bai, Tao","Xie, Xuelei","Zhang, Li","Li, Caihong","Yuan, Ye","Chen, Hua","Li, Huadong","Huang, Hanping","Tu, Shengjing","Gong, Fengyun","Liu, Ying","Wei, Yuan","Dong, Chongya","Zhou, Fei","Gu, Xiaoying","Xu, Jiuyang","Liu, Zhibo","Zhang, Yi","Li, Hui","Shang, Lianhan","Wang, Ke","Li, Kunxia","Zhou, Xia","Dong, Xuan","Qu, Zhaohui","Lu, Sixia","Hu, Xujuan","Ruan, Shunan","Luo, Shanshan","Wu, Jing","Peng, Lu","Cheng, Fang","Pan, Lihong","Zou, Jun","Jia, Chunmin","Wang, Juan","Liu, Xia","Wang, Shuzhen","Wu, Xudong","Ge, Qin","He, Jing","Zhan, Haiyan","Qiu, Fang","Guo, Li","Huang, Chaolin","Jaki, Thomas","Hayden, Frederick G","Horby, Peter W","Zhang, Dingyu","Wang, Chen"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32187464","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1056/NEJMoa2001282","link_comment_in":"32369286","locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1666138492519841792,"score":245.43668},{"pmid":32438446,"title":"Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.","text":["Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.","There is a rapidly expanding literature on the in vitro antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against SARS-CoV-2. However, this has not been accompanied by a comprehensive evaluation of the target plasma and lung concentrations of these drugs following approved dosing in humans. Accordingly, EC90 values recalculated from in vitro anti-SARS-CoV-2 activity data was expressed as a ratio to the achievable maximum plasma concentrations (Cmax) at an approved dose in humans (Cmax/EC90 ratio). Only 14 of the 56 analysed drugs achieved a Cmax/EC90 ratio above 1. A more in-depth assessment demonstrated that only nitazoxanide, nelfinavir, tipranavir (ritonavir-boosted) and sulfadoxine achieved plasma concentrations above their reported anti-SARS-CoV-2 activity across their entire approved dosing interval. An unbound lung to plasma tissue partition coefficient (Kp Ulung ) was also simulated to derive a lung Cmax/EC50 as a better indicator of potential human efficacy. Hydroxychloroquine, chloroquine, mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavir-boosted), ivermectin, azithromycin and lopinavir (ritonavir-boosted) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC50 . Nitazoxanide and sulfadoxine also exceeded their reported EC50 by 7.8- and 1.5-fold in lung, respectively. This analysis may be used to select potential candidates for further clinical testing, while deprioritising compounds unlikely to attain target concentrations for antiviral activity. Future studies should focus on EC90 values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials.","Clin Pharmacol Ther","Arshad, Usman","Pertinez, Henry","Box, Helen","Tatham, Lee","Rajoli, Rajith Kr","Curley, Paul","Neary, Megan","Sharp, Joanne","Liptrott, Neill J","Valentijn, Anthony","David, Christopher","Rannard, Steve P","O'Neill, Paul M","Aljayyoussi, Ghaith","Pennington, Shaun","Ward, Stephen A","Hill, Andrew","Back, David J","Khoo, Saye H","Bray, Patrick G","Biagini, Giancarlo A","Owen, Andrew","32438446"],"abstract":["There is a rapidly expanding literature on the in vitro antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against SARS-CoV-2. However, this has not been accompanied by a comprehensive evaluation of the target plasma and lung concentrations of these drugs following approved dosing in humans. Accordingly, EC90 values recalculated from in vitro anti-SARS-CoV-2 activity data was expressed as a ratio to the achievable maximum plasma concentrations (Cmax) at an approved dose in humans (Cmax/EC90 ratio). Only 14 of the 56 analysed drugs achieved a Cmax/EC90 ratio above 1. A more in-depth assessment demonstrated that only nitazoxanide, nelfinavir, tipranavir (ritonavir-boosted) and sulfadoxine achieved plasma concentrations above their reported anti-SARS-CoV-2 activity across their entire approved dosing interval. An unbound lung to plasma tissue partition coefficient (Kp Ulung ) was also simulated to derive a lung Cmax/EC50 as a better indicator of potential human efficacy. Hydroxychloroquine, chloroquine, mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavir-boosted), ivermectin, azithromycin and lopinavir (ritonavir-boosted) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC50 . Nitazoxanide and sulfadoxine also exceeded their reported EC50 by 7.8- and 1.5-fold in lung, respectively. This analysis may be used to select potential candidates for further clinical testing, while deprioritising compounds unlikely to attain target concentrations for antiviral activity. Future studies should focus on EC90 values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials."],"journal":"Clin Pharmacol Ther","authors":["Arshad, Usman","Pertinez, Henry","Box, Helen","Tatham, Lee","Rajoli, Rajith Kr","Curley, Paul","Neary, Megan","Sharp, Joanne","Liptrott, Neill J","Valentijn, Anthony","David, Christopher","Rannard, Steve P","O'Neill, Paul M","Aljayyoussi, Ghaith","Pennington, Shaun","Ward, Stephen A","Hill, Andrew","Back, David J","Khoo, Saye H","Bray, Patrick G","Biagini, Giancarlo A","Owen, Andrew"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438446","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/cpt.1909","keywords":["covid-19","coronavirus","lung","pharmacokinetics","sars-cov-2"],"locations":["lung"],"e_drugs":["Ritonavir","nitazoxanide","Chloroquine","Mefloquine","Azithromycin","Nelfinavir","Ivermectin","tipranavir","Sulfadoxine","Hydroxychloroquine","Lopinavir","Atazanavir Sulfate"],"topics":["Treatment"],"weight":1,"_version_":1667521393853464576,"score":244.93114},{"pmid":32418730,"title":"\"Off-label\" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.","text":["\"Off-label\" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.","INTRODUCTION: COVID-19 is an unprecedented challenge for physicians and scientists. Several publicized drugs are being used with not much evidence of their efficacy such as hydroxychloroquine, azithromycin or lopinavir-ritonavir. Yet, the cardiac safety of these drugs in COVID-19 deserves scrutiny as they are known to foster cardiac adverse ADRs, notably QTc interval prolongation on the electrocardiogram and its arrhythmogenic consequences. METHODS: Since March 27th, 2020, the French Pharmacovigilance Network directed all cardiac adverse drug reactions associated with \"off-label\" use of hydroxychloroquine, azithromycin and lopinavir-ritonavir in COVID-19 to the Nice Regional Center of Pharmacovigilance. Each Regional Center of Pharmacovigilance first assessed causality of drugs. We performed a specific analysis of these cardiac adverse drug reactions amidst an array of risk factors, reassessed the electrocardiograms and estimated their incidence in coronavirus disease 2019. RESULTS: In one month, 120 reports of cardiac adverse drug reactions have been notified, 103 of which associated with hydroxychloroquine alone (86%), or associated with azithromycin (60%). Their estimated incidence is 0.77% to 1.54% of all patients, notwithstanding strong underreporting. Lopinavir-ritonavir came third with 17 reports (14%) and chloroquine fourth with 3 reports (2.5%). There were 8 sudden, unexplained or aborted deaths (7%), 8 ventricular arrhythmias (7%), 90 reports of prolonged QTc (75%) most of them \"serious\" (64%), 48 of which proved >/= 500ms, 20 reports of severe conduction disorders (17%) and 5 reports of other cardiac causes (4%). Six reports derived from automedication. DISCUSSION AND CONCLUSION: \"Off-label\" use of treatments in COVID-19 increases the risk of cardiac ADRs, some of them avoidable. Even if these drugs are perceived as familiar, they are used in patients with added risk factors caused by infection. Precautions should be taken to mitigate the risk, even if they will be proven efficacious.","Therapie","Gerard, Alexandre","Romani, Serena","Fresse, Audrey","Viard, Delphine","Parassol, Nadege","Granvuillemin, Aurelie","Chouchana, Laurent","Rocher, Fanny","Drici, Milou-Daniel","32418730"],"abstract":["INTRODUCTION: COVID-19 is an unprecedented challenge for physicians and scientists. Several publicized drugs are being used with not much evidence of their efficacy such as hydroxychloroquine, azithromycin or lopinavir-ritonavir. Yet, the cardiac safety of these drugs in COVID-19 deserves scrutiny as they are known to foster cardiac adverse ADRs, notably QTc interval prolongation on the electrocardiogram and its arrhythmogenic consequences. METHODS: Since March 27th, 2020, the French Pharmacovigilance Network directed all cardiac adverse drug reactions associated with \"off-label\" use of hydroxychloroquine, azithromycin and lopinavir-ritonavir in COVID-19 to the Nice Regional Center of Pharmacovigilance. Each Regional Center of Pharmacovigilance first assessed causality of drugs. We performed a specific analysis of these cardiac adverse drug reactions amidst an array of risk factors, reassessed the electrocardiograms and estimated their incidence in coronavirus disease 2019. RESULTS: In one month, 120 reports of cardiac adverse drug reactions have been notified, 103 of which associated with hydroxychloroquine alone (86%), or associated with azithromycin (60%). Their estimated incidence is 0.77% to 1.54% of all patients, notwithstanding strong underreporting. Lopinavir-ritonavir came third with 17 reports (14%) and chloroquine fourth with 3 reports (2.5%). There were 8 sudden, unexplained or aborted deaths (7%), 8 ventricular arrhythmias (7%), 90 reports of prolonged QTc (75%) most of them \"serious\" (64%), 48 of which proved >/= 500ms, 20 reports of severe conduction disorders (17%) and 5 reports of other cardiac causes (4%). Six reports derived from automedication. DISCUSSION AND CONCLUSION: \"Off-label\" use of treatments in COVID-19 increases the risk of cardiac ADRs, some of them avoidable. Even if these drugs are perceived as familiar, they are used in patients with added risk factors caused by infection. Precautions should be taken to mitigate the risk, even if they will be proven efficacious."],"journal":"Therapie","authors":["Gerard, Alexandre","Romani, Serena","Fresse, Audrey","Viard, Delphine","Parassol, Nadege","Granvuillemin, Aurelie","Chouchana, Laurent","Rocher, Fanny","Drici, Milou-Daniel"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418730","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.therap.2020.05.002","keywords":["arrhythmia","azithromycin","covid-19","cardiac adverse effects","hydroxychloroquine","lopinavir","qtc prolongation"],"locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"e_drugs":["lopinavir-ritonavir drug combination","Hydroxychloroquine","Azithromycin","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1667159284433027072,"score":232.15942}]}